CBT-004, if approved, would be the first and only treatment for pinguecula, an ophthalmic condition impacting more than 50 ...
BriaCell (BCTX) Therapeutics presents positive Phase 2 survival, and Phase 3 biomarker data across three clinical posters at the 2025 San Antonio Breast Cancer Symposium, SABCS, taking place December ...